BIONTECH SE (BNTX) News
Filter BNTX News Items
BNTX News Results
|Loading, please wait...|
BNTX News Highlights
- For BNTX, its 30 day story count is now at 63.
- Over the past 27 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- PFE, MRNA and SE are the most mentioned tickers in articles about BNTX.
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
Vaccine stocks Moderna, BioNTech and Pfizer toppled Monday after a bevy of scientists argued against Covid booster shots.
An article in the Lancet suggested that a booster shot wouldn't be necessary for most people after a review of data from clinical trials, as well as efficacy in the real world.
Dr. Susannah Hills, Pediatric Airway Surgeon and Assistant Professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.
Israel is considering a fourth round of coronavirus vaccines, Bloomberg News reported, citing an interview a health ministry official gave to a local radio station. "We don't know when it will happen; I hope very much that it won't be within six months, like this time, and that the third dose will last for longer," Health Ministry Director General Nachman Ash said in an interview with Radio 103FM,
Vaccine stocks dipped Friday after the FDA said it expects to authorize Covid shots for children "in the coming months."
The FDA said that clinical trials testing COVID-19 vaccines for children are expected to include a monitoring period of at least two months after half the participants get the shots to ensure safety. The comments come as vaccine makers race to submit clinical data seeking regulatory approval for vaccines in children below 12. Earlier on Friday, Pfizer Inc's (NYSE: PFE) partner BioNTech SE (NASDAQ: BNTX) said it was set to request global approval to use its COVID-19 vaccine in children as young a
BioNTech SE (NASDAQ: BNTX) is reportedly prepping a launch for its mRNA-based COVID-19 vaccine developed with Pfizer Inc (NYSE: PFE) for children between 5 and 11 years old. Also read: Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years. BioNTech CMO Özlem Türeci told the weekly German magazine, Der Spiegel, that the Company would file the results of its trial in 5- to 11-year-olds with regulators across the world "over the next few weeks," reported Reuters. The Company a
BioNTech expects to apply worldwide for approval of its Covid vaccine for children ages 5 to 11, a media report says.
BioNTech is set to request approval across the globe to use its COVID-19 vaccine in children as young as five over the next few weeks and preparations for a launch are on track, the biotech firm's two top executives told Der Spiegel. "Already over the next few weeks we will file the results of our trial in five to 11 year olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe," Chief Medical Officer Oezlem Tuereci told the news weekly. The confident statements underscore the lead that BioNTech, which collaborates with Pfizer, holds in the race to win broad approval to vaccinate children below the age of 12 in Western countries.